ARCA Biopharma Receives Complete Response Letter From FDA On The GencaroTM NDA
ARCA biopharma, Inc. (Nasdaq:ABIO) announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA, or the Agency) for its New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure.
More: continued here
Filed under: Cardiovascular on June 4th, 2009
You must be logged in to post a comment.